{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T23:13:22Z","timestamp":1779232402003,"version":"3.51.4"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,7,4]],"date-time":"2020-07-04T00:00:00Z","timestamp":1593820800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,7,4]],"date-time":"2020-07-04T00:00:00Z","timestamp":1593820800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Surg Onc"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>Gallbladder cancer (GBC) is the most common and aggressive extra hepatic biliary tree cancer (BTC) with dismal outcome. Complete surgical resection is the treatment of choice. Chemotherapy is used for palliation in advanced GBC where surgery is not possible, and the most commonly used agent is gemcitabine in combination with cisplatin or oxaliplatin or with capecitabine regimens. Complete remissions are hardly encountered in these cases; therefore, it is important to combine standard therapies with molecular targeting.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Case presentation<\/jats:title>\n<jats:p>A 60-year-old woman presented with pain in abdomen and loss of appetite for 1 month, and imaging showed locally advanced gallbladder carcinoma with liver metastasis. After biopsy confirmation, patient was initially started on gemcitabine and oxaliplatin combination followed by gene sequencing, which showed Tp53 (exon 7\u2014c.713\u2009G &gt; A and exon 5\u2014c.376-2A &gt; G) and EGFR (exon 20\u2014T790M) mutation, and erlotinib was added to chemotherapy, after 6\u2009cycles of chemotherapy patient showed a 90% partial radiological response as per RECIST criteria.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusion<\/jats:title>\n<jats:p>This case reports the possible efficacy of erlotinib in combination with gemcitabine and oxaliplatin in treating an EGFR<jats:italic>-<\/jats:italic>mutated GBC with liver metastasis. To our knowledge, this is the first article reporting the response to erlotinib combination therapy with this particular solitary mutation.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s12957-020-01934-4","type":"journal-article","created":{"date-parts":[[2020,7,4]],"date-time":"2020-07-04T14:02:22Z","timestamp":1593871342000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Gallbladder cancer with EGFR mutation and its response to GemOx with erlotinib: a case report and review of literature"],"prefix":"10.1186","volume":"18","author":[{"given":"Kishan","family":"Soni","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tarun","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1496-9846","authenticated-orcid":false,"given":"Manoj","family":"Pandey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,7,4]]},"reference":[{"key":"1934_CR1","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1634\/theoncologist.2009-0302","volume":"15","author":"AX Xiu","year":"2010","unstructured":"Xiu AX, Hong TS, Hezel AF, Kooby DA. Current management of gallbladder carcinoma. Oncologist. 2010;15:168\u201381.","journal-title":"Oncologist"},{"key":"1934_CR2","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","volume":"362","author":"J Valle","year":"2010","unstructured":"Valle J, Wasan H, Palmer DH, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010;362:1273\u201381.","journal-title":"N Engl J Med"},{"key":"1934_CR3","doi-asserted-by":"publisher","unstructured":"El-Khoueiry AB, Rankin C, Siegel AB, Iqbal S, Gong IY, Micetich KC, Kayaleh OR, Lenz HJ, Blanke CD. S0941: a phase 2 SWOG study of sorafenib and erlotinib in patients with advanced gallbladder carcinoma or cholangiocarcinoma. Br J Cancer 2014 Feb 18;110(4):882-887. doi: https:\/\/doi.org\/10.1038\/bjc.2013.801.Epub 2014 Jan14. PMID: 24423918.","DOI":"10.1038\/bjc.2013.801"},{"key":"1934_CR4","doi-asserted-by":"publisher","unstructured":"Li M, Zhang Z, Li X, Ye J, Wu X, Tan Z, Liu C, Shen B, Wang XA, Wu W, Zhou D, Zhang D, Wang T, Liu B, Qu K, Ding Q, Weng H, Ding Q, Mu J, Shu Y, Bao R, Cao Y, Chen P, Liu T, Jiang L, Hu Y, Dong P, Gu J, Lu W, Shi W, Lu J, Gong W, Tang Z, Zhang Y, Wang X, Chin YE, Weng X, Zhang H, Tang W, Zheng Y, He L, Wang H, Liu Y, Liu Y. Whole-exome and targeted gene sequencing of gallbladder carcinoma identifies recurrent mutations in the ErbB pathway. Nat Genet. 2014 Aug;46(8):872-876. doi: https:\/\/doi.org\/10.1038\/ng.3030. Epub 2014 Jul 6. PMID: 24997986.","DOI":"10.1038\/ng.3030"},{"key":"1934_CR5","doi-asserted-by":"publisher","unstructured":"Peraldo-Neia C, Cavalloni G, Fenocchio E, Cagnazzo C, Gammaitoni L, Cereda S, Nasti G, Satolli MA, Aprile G, Reni M, Avallone A, Spadi R, Venesio T, Martin V, Doglioni C, Frattini M, Aglietta M, Leone F. Prognostic and predictive role of EGFR pathway alterations in biliary cancer patients treated with chemotherapy and anti-EGFR. PLoS One 2018 Jan 19;13(1):e0191593. doi: https:\/\/doi.org\/10.1371\/journal.pone.0191593. eCollection 2018. PMID: 29352306.","DOI":"10.1371\/journal.pone.0191593"},{"key":"1934_CR6","doi-asserted-by":"publisher","unstructured":"Sharma A, Kumar A, Kumari N, Krishnani N, Rastogi N. Mutational frequency of KRAS, NRAS, IDH2, PIK3CA, and EGFR in north Indian gallbladder cancer patients. Ecancermedicalscience. 2017 Aug 7;11:757. doi: https:\/\/doi.org\/10.3332\/ecancer.2017.757. eCollection2017. PMID: 2890047.","DOI":"10.3332\/ecancer.2017.757"},{"key":"1934_CR7","doi-asserted-by":"publisher","unstructured":"Pignochino Y, Sarotto I, Peraldo-Neia C, Penachioni JY, Cavalloni G, Migliardi G, Casorzo L, Chiorino G, Risio M, Bardelli A, Aglietta M, Leone F. Targeting EGFR\/HER2 pathways enhances the antiproliferative effect of gemcitabine in biliary tract and gallbladder carcinomas. BMC Cancer. 2010 Nov 18;10:631. doi: https:\/\/doi.org\/10.1186\/1471-2407-10-631.PMID: 21087480.","DOI":"10.1186\/1471-2407-10-631"},{"key":"1934_CR8","unstructured":"Tarceva prescribing information. https:\/\/www.gene.com\/download\/pdf\/tarceva_prescribing.pdf. Accessed 3 July 2020."},{"key":"1934_CR9","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/0753-3322(89)90003-6","volume":"43","author":"G Mathe","year":"1989","unstructured":"Mathe G, Kidani Y, Segiguchi M, et al. Oxalato-platinum or 1-OHP, a third-generation platinum complex: an experimental and clinical appraisal and preliminary comparison with cis-platinum and carboplatinum. Biomed Pharmacother. 1989;43:237\u201350.","journal-title":"Biomed Pharmacother"},{"key":"1934_CR10","doi-asserted-by":"crossref","unstructured":"Shigematsu H, Lin L, Takahashi T, et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 2005;97:339\u2013346. [PubMed: 15741570].","DOI":"10.1093\/jnci\/dji055"},{"key":"1934_CR11","doi-asserted-by":"crossref","unstructured":"Sequist LV, Bell DW, Lynch TJ, Haber DA. Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer. J Clin Oncol 2007;25:587\u2013595. [PubMed: 17290067].","DOI":"10.1200\/JCO.2006.07.3585"},{"key":"1934_CR12","doi-asserted-by":"crossref","unstructured":"Mitsudomi T, Kosaka T, Endoh H, et al. Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. J Clin Oncol 2005;23:2513\u20132520. [PubMed: 15738541].","DOI":"10.1200\/JCO.2005.00.992"},{"key":"1934_CR13","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1158\/1535-7163.MCT-12-0620","volume":"12","author":"ME Arcila","year":"2013","unstructured":"Arcila ME, et al. EGFR exon 20 insertion mutations in lung adenocarcinomas: prevalence, molecular heterogeneity, and clinicopathologic characteristics. Mol Cancer Ther. 2013;12:220\u20139.","journal-title":"Mol Cancer Ther"},{"key":"1934_CR14","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1111\/cas.12996","volume":"107","author":"Y Kobayashi","year":"2016","unstructured":"Kobayashi Y, Mitsudomi T. Not all epidermal growth factor receptor mutations in lung cancer are created equal: perspectives for individualized treatment strategy. Cancer Sci. 2016;107:1179\u201386.","journal-title":"Cancer Sci"},{"key":"1934_CR15","doi-asserted-by":"publisher","unstructured":"Lee, J., Park, S. H., Chang, H. M., Kim, J. S., Choi, H. J., Lee, M. A., Chang, J. S., Jeung, H. C., Kang, J. H., Lee, H. W., Shin, D. B., Kang, H. J., Sun, J. M., Park, J. O., Park, Y. S., Kang, W. K., & Lim, H. Y. (2012). Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 study. Lancet Oncol, 13(2), 181-188. https:\/\/doi.org\/https:\/\/doi.org\/10.1016\/S1470-2045(11)70301-1.","DOI":"10.1016\/S1470-2045(11)70301-1"},{"key":"1934_CR16","doi-asserted-by":"publisher","unstructured":"Mody K, Strauss E, Lincer R, Frank RC. Complete response in gallbladder cancer to erlotinib plus gemcitabine does not require mutation of the epidermal growth factor receptor gene: a case report. BMC Cancer. 2010;10:570. Published 2010 Oct 20. doi:https:\/\/doi.org\/10.1186\/1471-2407-10-570.","DOI":"10.1186\/1471-2407-10-570"},{"key":"1934_CR17","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/S1470-2045(11)70393-X","volume":"13","author":"R Rosell","year":"2012","unstructured":"Rosell R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012;13:239\u201346.","journal-title":"Lancet Oncol"},{"key":"1934_CR18","doi-asserted-by":"publisher","first-page":"5034","DOI":"10.1200\/JCO.2006.06.3958","volume":"24","author":"FR Hirsch","year":"2006","unstructured":"Hirsch FR, et al. Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer. J Clin Oncol. 2006;24:5034\u201342.","journal-title":"J Clin Oncol"},{"key":"1934_CR19","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1056\/NEJMoa0810699","volume":"361","author":"TS Mok","year":"2009","unstructured":"Mok TS, et al. Gefitinib or carboplatin\u2013paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361:947\u201357.","journal-title":"N Engl J Med"},{"key":"1934_CR20","doi-asserted-by":"publisher","first-page":"5764","DOI":"10.1158\/1078-0432.CCR-06-0714","volume":"12","author":"T Kosaka","year":"2006","unstructured":"Kosaka T, et al. Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib. Clin Cancer Res. 2006;12:5764\u20139.","journal-title":"Clin Cancer Res"},{"key":"1934_CR21","doi-asserted-by":"publisher","unstructured":"Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004; 350(21):2129\u20132139. https:\/\/doi.org\/https:\/\/doi.org\/10.1056\/NEJMoa040938 PMID: 15118073.","DOI":"10.1056\/NEJMoa040938"},{"key":"1934_CR22","doi-asserted-by":"publisher","unstructured":"Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004; 304(5676):1497\u20131500. https:\/\/doi.org\/\nhttps:\/\/doi.org\/10.1126\/science.1099314 PMID: 15118125.","DOI":"10.1126\/science.1099314"},{"key":"1934_CR23","doi-asserted-by":"publisher","unstructured":"Pao W, Miller V, Zakowski M, Doherty J, Politi K, Sarkaria I, et al. EGF receptor gene mutations are common in lung cancers from \u201cnever smokers\u201d and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A. 2004; 101(36):13306\u201313311. https:\/\/doi.org\/https:\/\/doi.org\/10.1073\/pnas.0405220101 PMID: 15329413.","DOI":"10.1073\/pnas.0405220101"},{"key":"1934_CR24","doi-asserted-by":"publisher","first-page":"2070","DOI":"10.1073\/pnas.0709662105","volume":"105","author":"C-H Yun","year":"2008","unstructured":"Yun C-H, et al. The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc Natl Acad Sci. 2008;105:2070\u20135.","journal-title":"Proc Natl Acad Sci"},{"key":"1934_CR25","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/j.bbapap.2009.12.010","volume":"1804","author":"MJ Eck","year":"2010","unstructured":"Eck MJ, Yun CH. Structural and mechanistic underpinnings of the differential drug sensitivity of EGFR mutations in non-small cell lung cancer. Biochim Biophys Acta. 2010;1804:559\u201366.","journal-title":"Biochim Biophys Acta"},{"key":"1934_CR26","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1007\/s00432-005-0016-1","volume":"131","author":"G-Y Gwak","year":"2005","unstructured":"Gwak G-Y, Yoon J-H, Shin CM, Ahn YJ, Chung JK, Kim YA, et al. Detection of response-predicting mutations in the kinase domain of the epidermal growth factor receptor gene in cholangiocarcinoma. J Cancer Res Clin Oncol. 2005;131:649\u201362.","journal-title":"J Cancer Res Clin Oncol"},{"key":"1934_CR27","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.1158\/1078-0432.CCR-05-1692","volume":"12","author":"F Leone","year":"2006","unstructured":"Leone F, Cavalloni G, Pignochino Y, Sarotto I, Ferraris R, Piacibello W, et al. Somatic mutations of epidermal growth factor receptor in bile duct and gallbladder carcinoma. Clin Cancer Res. 2006;12:1680\u20135.","journal-title":"Clin Cancer Res"},{"issue":"8","key":"1934_CR28","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1002\/ijc.31916","volume":"144","author":"P Iyer","year":"2019","unstructured":"Iyer P, Shrikhande SV, Ranjan M, et al. ERBB2 and KRAS alterations mediate response to EGFR inhibitors in early stage gallbladder cancer. Int J Cancer. 2019;144(8):2008\u201319. https:\/\/doi.org\/10.1002\/ijc.31916.","journal-title":"Int J Cancer"}],"container-title":["World Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-020-01934-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12957-020-01934-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-020-01934-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,3]],"date-time":"2021-07-03T23:09:12Z","timestamp":1625353752000},"score":1,"resource":{"primary":{"URL":"https:\/\/wjso.biomedcentral.com\/articles\/10.1186\/s12957-020-01934-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,4]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1934"],"URL":"https:\/\/doi.org\/10.1186\/s12957-020-01934-4","relation":{},"ISSN":["1477-7819"],"issn-type":[{"value":"1477-7819","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,4]]},"assertion":[{"value":"21 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 July 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Ethical approval is not required as patient consent for publication was obtained.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The written consent for publication of case report and accompanied images was obtained from the patient.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that there are no competing interests","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"153"}}